# Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon

> **NCT03869866** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 290 (actual)

## Conditions studied

- Healthy Volunteers (Meningococcal Infection)

## Interventions

- **BIOLOGICAL:** Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine

## Key facts

- **NCT ID:** NCT03869866
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-09
- **Primary completion:** 2022-03-18
- **Final completion:** 2022-03-18
- **Target enrollment:** 290 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03869866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03869866, "Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03869866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*